NUCALA is indicated for the add-on maintenance treatment of patients 12 years and older with severe asthma with an eosinophilic phenotype. NUCALA is not indicated for the relief of acute bronchospasm or status asthmaticus.
*Source: IQVIA - NPATM audit: 12 mo. TRX data ending 11/18 (All rights reserved).
†December 2015 to November 2018 data sourced from IQVIA and GSK. Claims data based on
‡MENSA (Trial 2):
§SIRIUS (Trial 3):
‖COLUMBA: 4.5-year open-label study assessing the safety, immunogenicity, and efficacy of
- Data on file, GSK.
- Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371:1198-1207.
- Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371:1189-1197.
- Khatri S, Moore W, Gibson PG, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma [published online ahead of print, October 22, 2018]. J Allergy Clin Immunol. doi.org/10.1016/j.jaci.2018.09.033.